Payment overview · 2025
General Payments
$129.13
8 reported records · 5 companies
Healthcare provider profile · identity verified
David Reinhard, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHURUBUSCO, IN · NPI 1508843095
Verified facts
What the public records show
CMS Open Payments records show David Reinhard, M.D. received $129.13 in general payments during 2025 across 8 reported records.
Amgen Inc. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.78 | 26.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.52 | 26.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.08 | 23.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.02 | 12.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.73 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $129.13 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.78 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.78 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.52 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 167 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 804 | 212 |
| Levothyroxine Sodium | Levothyroxine Sodium | 703 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 589 | 166 |
| Lisinopril | Lisinopril | 460 | 126 |
| Metformin Hcl | Metformin Hcl | 453 | 129 |
| Omeprazole | Omeprazole | 395 | 124 |
| Losartan Potassium | Losartan Potassium | 315 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 315 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 306 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 292 | 100 |
| Simvastatin | Simvastatin | 286 | 75 |
| Carvedilol | Carvedilol | 252 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 81 |
| Gabapentin | Gabapentin | 236 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 55 |
| Furosemide | Furosemide | 202 | 50 |
| Meloxicam | Meloxicam | 194 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 65 |
| Famotidine | Famotidine | 173 | 54 |
| Glimepiride | Glimepiride | 173 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 37 |
| Jardiance | Empagliflozin | 167 | 39 |
| Tramadol Hcl | Tramadol Hcl | 163 | 35 |
| Sertraline Hcl | Sertraline Hcl | 161 | 45 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 139 | 37 |
| Atenolol | Atenolol | 127 | 24 |
| Prednisone | Prednisone | 126 | 62 |
| Alprazolam | Alprazolam | 125 | 23 |
| Montelukast Sodium | Montelukast Sodium | 125 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 124 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 33 |
| Trazodone Hcl | Trazodone Hcl | 119 | 32 |
| Eliquis | Apixaban | 116 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 50 |
| Potassium Chloride | Potassium Chloride | 115 | 38 |
| Buspirone Hcl | Buspirone Hcl | 111 | 36 |
| Bupropion Xl | Bupropion Hcl | 107 | 24 |
| Lorazepam | Lorazepam | 105 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 29 |
| Ezetimibe | Ezetimibe | 104 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 31 |
| Ondansetron Odt | Ondansetron | 81 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 20 |
| Clonazepam | Clonazepam | 78 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 18 |
| Trulicity | Dulaglutide | 71 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 69 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 18 |
| Allopurinol | Allopurinol | 66 | 19 |
| Azithromycin | Azithromycin | 64 | 48 |
| Pregabalin | Pregabalin | 64 | 14 |
| Cephalexin | Cephalexin | 61 | 51 |
| Donepezil Hcl | Donepezil Hcl | 59 | 18 |
| Ozempic | Semaglutide | 55 | 16 |
| Synthroid | Levothyroxine Sodium | 55 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 53 | 18 |
| Metformin Hcl Er | Metformin Hcl | 51 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | 14 |
| Torsemide | Torsemide | 47 | 14 |
| Benazepril Hcl | Benazepril Hcl | 43 | 11 |
| Celecoxib | Celecoxib | 42 | 14 |
| Topiramate | Topiramate | 42 | suppressed |
| Mupirocin | Mupirocin | 41 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 12 |
| Amoxicillin | Amoxicillin | 40 | 24 |
| Spironolactone | Spironolactone | 39 | 15 |
| Diazepam | Diazepam | 38 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 12 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 23 |
| Droplet Pen Needle | Pen Needle, Diabetic | 31 | 11 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | 13 |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 21 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Belsomra | Suvorexant | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 23 |
| Nystatin | Nystatin | 26 | 16 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 13 |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 14 |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.13 · 8 records | Amgen Inc. | CAPLYTA, Cologuard Collection Kit, JARDIANCE, OTEZLA, QULIPTA, REPATHA, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error